methyl 3-(2-tetrahydrofuryl)-3-oxopropanoate | 252366-36-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: methyl 3-(2-tetrahydrofuryl)-3-oxopropanoate
• 英文别名: methyl 3-oxo-3-(tetrahydrofuran-2-yl)propanoate；methyl 3-oxo-3-(oxolan-2-yl)propanoate
• CAS: 252366-36-2
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: MTMWQZUNBMTJQT-UHFFFAOYSA-N

物化性质

• 沸点：
  251.9±30.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-(2-tetrahydrofuryl)-3-oxopropanoate 在 吡啶 、 sodium chlorite 、 potassium dihydrogenphosphate 、 2-甲基-2-丁烯 、 溶剂黄146 、 叔丁醇 、 三氯氧磷 作用下， 以 水 、 甲苯 为溶剂， 反应 192.75h， 生成 (+/-)-1-methyl-3-oxo-2-phenyl-5-(tetrahydrofuran-2-yl)-2,3-dihydro-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series

  摘要：

  As part of our effort toward developing an effective therapeutic agent for c-Met-dependent tumors, a pyrazolone-based class II c-Met inhibitor, N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (1), was identified. Knowledge of the binding mode of this molecule in both c-Met and VEGFR-2 proteins led to a novel strategy for designing more selective analogues of 1. Along with detailed SAR information, we demonstrate that the low kinase selectivity associated with class II c-Met inhibitors can be improved significantly. This work resulted in the discovery of potent c-Met inhibitors with improved selectivity profiles over VEGFR-2 and IGF-1R that could serve as useful tools to probe the relationship between kinase selectivity and in vivo efficacy in tumor xenograft models. Compound 59e (AMG 458) was ultimately advanced into preclinical safety studies.

  DOI：

  10.1021/jm201331s
• 作为产物：
  描述：

  2-四氢呋喃甲酸 、 丙二酸环(亚)异丙酯 生成 methyl 3-(2-tetrahydrofuryl)-3-oxopropanoate
  参考文献：
  名称：

  2-呋喃乙酸甲酯及其类似物在酒石酸改性雷尼镍上的对映异构加氢

  摘要：

  2-呋喃酰乙酸甲酯在 TA-MRNi 上的氢化还原了三个不饱和键，得到四氢-2-呋喃酰乙酸甲酯，其 3-位的对映体过量 (ee) 为 77%，而 4-位是外消旋的。在相同条件下，4-甲氧基羰基类似物的底物仅将酮部分氢化，得到相应的具有呋喃环的手性仲醇，69% ee。

  DOI：

  10.1246/cl.1999.1055

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• [EN] HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROARYLDIHYDROPYRIMIDINE ET MÉTHODES DE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019001420A1

  公开（公告）日：2019-01-03

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了一些用于治疗HBV感染的化合物，以及其药物组合物和抑制、抑制或预防受试者HBV感染的方法。
• Enantio-Differentiating Hydrogenation of Methyl 2-Furoylacetate and Its Analogs over Tartaric Acid-Modified Raney Nickel
  作者：Satoshi Nakagawa、Noriko Haruna、Delicia E. Acosta、Tadateru Endo、Takashi Sugimura、Akira Tai

  DOI：10.1246/cl.1999.1055

  日期：1999.10

  Hydrogenation of methyl 2-furoylacetate over TA-MRNi reduced the three unsaturated bonds to give methyl tetrahydro-2-furoylacetate, the enantiomeric excess (ee) of which at the 3-position was 77%, whereas the 4-position was racemic. Under the same conditions, the substrate of 4-methoxycarbonyl analogue was resulted in hydrogenation of only the ketone moiety to give the corresponding chiral sec-alcohol

  2-呋喃酰乙酸甲酯在 TA-MRNi 上的氢化还原了三个不饱和键，得到四氢-2-呋喃酰乙酸甲酯，其 3-位的对映体过量 (ee) 为 77%，而 4-位是外消旋的。在相同条件下，4-甲氧基羰基类似物的底物仅将酮部分氢化，得到相应的具有呋喃环的手性仲醇，69% ee。
• HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Janssen Pharmaceutica NV

  公开号：US20200172532A1

  公开（公告）日：2020-06-04

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
• [EN] SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281<br/>[FR] PYRIMIDINE-5-CARBOXAMIDES SUBSTITUÉS
  申请人：ASTRAZENECA AB

  公开号：WO2009130496A1

  公开（公告）日：2009-10-29

  A compound of formula (I) and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.